Brind.

Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.

1 report, 1 independent Updated Aug 30

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Johnson & Johnson HUMIRA Amgen

How it developed

Newest first. Tap a step to see who reported it.

Jun 7MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.Sub-event
Aug 30JNJ tested nipocalimab against Humira; Amgen is noted for biosimilar competition in the market for Humira.1 source
- GuruFocus.com

Keep exploring

The entities involved

Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
- P&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Mon 00:50
- Johnson & Johnson separated its Consumer Health business into Kenvue on August 25, 2025.Sun 04:04
HUMIRA
Czech company
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Sun 13:48
- Lost patent protection for Humira in the US on August 20, 2025.Thu 06:13
Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05

Coverage

Newest first; wire copies grouped

Aug 30GuruFocus.comJohnson & Johnson Ends RA Combo After Mid-Stage Miss This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ) has dropped plans for a rheumatoid arthritis combo after its experimental d